|
|
| Can-Fite BioPharma Announces The Initiation Of Phase 3 In Dry Eye Syndrome | Wed, 08 Sep 2010 |
| Can-Fite BioPharma Ltd (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome... | |
| ThromboGenics Presents Positive Pooled Results From The MIVI-TRUST Phase III Program | Tue, 07 Sep 2010 |
| ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France... | |
|
| Stem Cell Ruling Halts Sight-Saving Research | Mon, 06 Sep 2010 |
| The Association for Research in Vision and Ophthalmology (ARVO), a professional organization of member scientists, opposes the Federal District Court injunction that froze federal funding for human embryonic stem cell (hESC) research. ARVO is troubled by this barrier to research that has the potential to restore sight and mitigate eye damage... | |
|
| Starting The School Year Right | Sat, 04 Sep 2010 |
| As many children head back to school this fall, are they truly prepared for what lies ahead? With a few simple medical exams; Maine's school-age children will be armed with the tools they need to have a healthier school year... | |
|
| 'Back-To-School' How To Prevent Sports Related Eye Injuries | Fri, 03 Sep 2010 |
| It's back to school time! Kids are feeling excited and maybe a little nervous. New teachers, new friends and new sports seasons. Parents are scrambling to buy back-to-school clothes and equip their children with all the sports gear they need, like helmets, pads, braces and mouth guards... | |
|
|
|
| Bausch + Lomb Releases Single-Use Vitreoretinal Asymmetric Peeling Forceps | Thu, 02 Sep 2010 |
| Bausch + Lomb Storz® Ophthalmic Instruments announces the U.S. release of a new, single-use, asymmetric peeling forceps for vitreoretinal surgery. The forceps are available in 23- and 25-gauge options for facilities seeking the safety, consistency and convenience a single-use instrument offers... | |
| New Data Will Help Predict Vision Loss In Glaucoma | Thu, 02 Sep 2010 |
| Eye M.D.s are intent on finding better ways to diagnose and treat glaucoma, a complex, potentially blinding disease. September's Ophthalmology journal includes new data from the Rotterdam Study that will help doctors better predict visual field loss (VFL) in glaucoma patients. Johannes R... | |
| Proprietary Zinc/Phytase Formulation Improved Botulinum Toxin A Results | Thu, 02 Sep 2010 |
| A recent study conducted by oculoplastic surgeon Charles Soparkar, M.D., Ph.D. (The Methodist Hospital, Houston, TX) utilizing a patent-pending formulation of zinc and phytase (trademarked as ZYTAZE?), demonstrated that increasing zinc levels by oral administration for 4 days prior to a planned injection of botulinum toxin improved efficacy and/or duration in 41 of 44 patients tested (93%)... | |
|
|
|
|
| Improving Ocular Disease Screening By LED Illumination Of The Eye | Wed, 01 Sep 2010 |
| A new imaging system using six different wavelengths to illuminate the interior of the eyeball (ocular fundus) may pave the way for doctors to easily screen patients for common diseases of the eye, such as age-related macular degeneration and diabetic retinopathy. The system is described in the journal Review of Scientific Instruments, which is published by the American Institute of Physics... | |
| Eyegenix? Artificial Cornea Achieves Major Advancement Towards Curing Corneal Blindness | Wed, 01 Sep 2010 |
| Eyegenix?, the ophthalmic division of Cellular Bioengineering, Inc. (CBI), announced that the results of a pilot clinical trial using a synthetic cornea for which Eyegenix? holds the exclusive global license for transplantation were published in the peer-reviewed journal, Science Translational Medicine (Volume 2, Issue 46, August, 25, 2010)... | |
| Diabetic Macular Edema Drug Iluvien Gets FDA Priority Review | Tue, 31 Aug 2010 |
| Iluvien(R) (fluocinolone acetonide intravitreal insert), an investigational sustained drug delivery system that releases sub-microgram levels of fluocinolone acetonide for DME (diabetic macular edema) treatment, has been accepted for filing and granted Priority Review States by the FDA (Food and Drug Administration, USA), Alimera Sciences, Inc. announced today... | |
| Optometrists Encourage Eye Test For Children, Ireland | Tue, 31 Aug 2010 |
| Optometrists are encouraging parents and teachers across the country to take their children for a special eye test as part of its Bright Eyes For Back to School campaign which runs next week (from September 6th to 11th)... | |
|
| Revolutionary Way To Treat Eye Cancer May Prevent Blindness | Tue, 31 Aug 2010 |
| Rare but devastating, eye cancer can strike anyone at any time and treating it often requires radiation that leaves half of all patients partially blind. But a new technique developed by Scott Oliver, MD, assistant professor at the University of Colorado School of Medicine, may change all that... | |
